新型抗炎大环内酯glasmacinal的早期临床药理学评估:耐受性、药代动力学与药物相互作用
该研究在两项健康受试者试验中评估了口服抗炎大环内酯glasmacinal(EP395)的药代动力学、安全性和耐受性,包括首次人体试验和药物相互作用试验。结果显示单次剂量达750 mg及多次剂量达375 mg均耐受良好,食物使暴露量降低约三分之一,维拉帕米显著增加glasmacinal暴露,而glasmacinal对咪达唑仑和地高辛暴露仅有轻度增加。
要点
- glasmacinal单次剂量达750 mg、多次剂量达375 mg均耐受良好,无严重不良事件。
- 食物使glasmacinal系统暴露(Cmax和AUC0-inf)降低约三分之一,建议关注给药与进食关系。
- 维拉帕米使glasmacinal的Cmax增加1.70倍、AUC0-inf增加2.41倍,提示其可能为CYP3A4/P-gp底物。
核心结论
- glasmacinal在健康受试者中单次剂量达750 mg和多次剂量达375 mg均耐受良好。
- glasmacinal可能是影响CYP3A4和/或P-gp的某些药物的底物,但不太可能是临床相关药物相互作用的促发者。
研究设计与样本
- 首次人体试验为随机、双盲、安慰剂对照试验,评估glasmacinal单次(20-750 mg)和多次(120-375 mg每日,共28天)给药。
- 药物相互作用试验为开放标签评估,考察维拉帕米对glasmacinal药代动力学的影响,以及glasmacinal对咪达唑仑和地高辛药代动力学的影响。
主要发现
- 未发生严重不良事件或重度不良事件,无因认为与glasmacinal相关的不良事件导致退出。
- glasmacinal吸收迅速,给药后约4小时达峰,终末半衰期约70小时。
- 300 mg单次剂量后进食使glasmacinal的Cmax和AUC0-inf降低约三分之一(平行组比较)。
- 合用维拉帕米使glasmacinal的Cmax增加1.70倍(90% CI: 1.52, 2.39),AUC0-inf增加2.41倍(90% CI: 2.18, 2.82)。
- glasmacinal使咪达唑仑的Cmax增加1.26倍(90% CI: 1.12, 1.49)、AUC0-inf增加1.54倍(90% CI: 1.33, 1.89),使地高辛的Cmax增加1.38倍(90% CI: 1.22, 1.81)、AUC0-inf增加1.37倍(90% CI: 1.26, 1.52)。
临床怎么用
- 临床使用glasmacinal时应关注与CYP3A4和/或P-gp强效抑制剂(如维拉帕米)的合用,可能显著增加glasmacinal暴露。
- 进食可降低glasmacinal暴露约三分之一,需结合临床试验设计考虑给药与餐食的时间安排。
- glasmacinal与CYP3A4底物(如咪达唑仑)或P-gp底物(如地高辛)合用时暴露轻度增加,但仍需保持警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti-inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: 'first-in-human' (FIH) and 'drug-drug-interaction' (DDI). METHODS: The FIH trial was a randomized, double-blind, placebo-controlled trial of single (20-750 mg) and multiple (120-375 mg daily for 28 days) doses of glasmacinal. The DDI trial was an open-label assessment of the effect of verapamil (moderate CYP3A4 inhibitor and P-gp inhibitor) on the PK of glasmacinal, and the effect of glasmacinal on the PK of midazolam (CYP3A4 substrate) and digoxin (P-gp substrate). RESULTS: No SAEs or severe AEs occurred, and no AEs considered related to glasmacinal led to withdrawal. Glasmacinal was rapidly absorbed, reaching peak plasma concentrations at ~4 h post-dose and a terminal half-life ~70 h. Glasmacinal systemic exposure (Cmax and AUC0-inf) was reduced by one third when administered after food (300-mg single dose, parallel group comparison). Co-administration of glasmacinal with verapamil increased glasmacinal exposure (Cmax 1.70-fold [90% CI: 1.52, 2.39], AUC0-inf 2.41-fold [90% CI: 2.18, 2.82]). Glasmacinal modestly increased exposure to midazolam (Cmax 1.26-fold [90% CI: 1.12, 1.49], AUC0-inf 1.54-fold [90% CI: 1.33, 1.89]) and digoxin (Cmax 1.38-fold [90% CI: 1.22, 1.81] and AUC0-inf 1.37-fold [90% CI: 1.26, 1.52]). CONCLUSIONS: Glasmacinal was well tolerated in single doses up to 750 mg and repeat doses up to 375 mg. Glasmacinal may be a victim of selected drugs that impact CYP3A4 and/or P-gp but is unlikely to be a perpetrator of clinically relevant DDIs.
引用
- Singh D, Hanrott K, Breuer O, et al. Early clinical pharmacology evaluation of the novel anti-inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions. Br J Clin Pharmacol. 2026. PMID: 41845869. doi:10.1002/bcp.70509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。